Physician profile
Milton D Soderberg
NPI 1255446506
$3,013.10
in general payments reported to CMS, 2019-2025
17 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $171 · 2021: $265 · 2022: $595 · 2023: $473 · 2024: $273 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.68 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $849.34 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $505.80 | 2019-2025 | Tremfya |
| Abbvie INC. | $322.13 | 2019-2025 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $245.44 | 2019-2020 | |
| Ucb, INC. | $242.08 | 2019-2024 | Cimzia, Bimzelx |
| Sun Pharmaceutical Industries INC. | $189.56 | 2019-2022 | |
| Amgen INC. | $134.60 | 2019-2021 | |
| Celgene Corporation | $121.04 | 2019 | |
| Pfizer INC. | $118.32 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $84.19 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $81.62 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $41.61 | 2022-2023 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.14 | 2023 | Spevigo |
| Astrazeneca Pharmaceuticals LP | $22.18 | 2022 | |
| Organogenesis INC. | $16.82 | 2023 | Puraply |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $15.23 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$335,826.42 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milton Soderberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.